PAVmed Inc.
PAVmed Inc. (PAVMW) Stock Competitors & Peer Comparison
See (PAVMW) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PAVMW | $0.03 | +105.67% | 769.7K | -0.05 | -$0.58 | N/A |
| ABT | $131.59 | -0.21% | 229B | 16.53 | $7.96 | +1.76% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| BSX | $106.39 | +1.22% | 157.6B | 63.33 | $1.68 | N/A |
| SYK | $394.33 | +0.88% | 150.8B | 52.10 | $7.57 | +0.84% |
| MDT | $92.18 | +0.15% | 118.1B | 25.46 | $3.62 | +3.05% |
| EW | $81.27 | +0.51% | 47.7B | 34.00 | $2.39 | N/A |
| DXCM | $76.12 | +0.21% | 29.9B | 53.61 | $1.42 | N/A |
| PHG | $27.81 | +0.76% | 25.8B | 146.29 | $0.19 | +3.19% |
| STE | $248.58 | +0.04% | 24.5B | 37.95 | $6.55 | +0.92% |
Stock Comparison
PAVMW vs ABT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ABT has a market cap of 229B. Regarding current trading prices, PAVMW is priced at $0.03, while ABT trades at $131.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ABT's P/E ratio is 16.53. In terms of profitability, PAVMW's ROE is +3.62%, compared to ABT's ROE of +0.32%. Regarding short-term risk, PAVMW is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ABT's competition here
PAVMW vs BSX-PA Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, PAVMW is priced at $0.03, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, PAVMW's ROE is +3.62%, compared to BSX-PA's ROE of +0.12%. Regarding short-term risk, PAVMW is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BSX-PA's competition here
PAVMW vs BSX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BSX has a market cap of 157.6B. Regarding current trading prices, PAVMW is priced at $0.03, while BSX trades at $106.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BSX's P/E ratio is 63.33. In terms of profitability, PAVMW's ROE is +3.62%, compared to BSX's ROE of +0.12%. Regarding short-term risk, PAVMW is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BSX's competition here
PAVMW vs SYK Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SYK has a market cap of 150.8B. Regarding current trading prices, PAVMW is priced at $0.03, while SYK trades at $394.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SYK's P/E ratio is 52.10. In terms of profitability, PAVMW's ROE is +3.62%, compared to SYK's ROE of +0.14%. Regarding short-term risk, PAVMW is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SYK's competition here
PAVMW vs MDT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, MDT has a market cap of 118.1B. Regarding current trading prices, PAVMW is priced at $0.03, while MDT trades at $92.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas MDT's P/E ratio is 25.46. In terms of profitability, PAVMW's ROE is +3.62%, compared to MDT's ROE of +0.13%. Regarding short-term risk, PAVMW is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check MDT's competition here
PAVMW vs EW Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, EW has a market cap of 47.7B. Regarding current trading prices, PAVMW is priced at $0.03, while EW trades at $81.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas EW's P/E ratio is 34.00. In terms of profitability, PAVMW's ROE is +3.62%, compared to EW's ROE of +0.41%. Regarding short-term risk, PAVMW is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check EW's competition here
PAVMW vs DXCM Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, DXCM has a market cap of 29.9B. Regarding current trading prices, PAVMW is priced at $0.03, while DXCM trades at $76.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas DXCM's P/E ratio is 53.61. In terms of profitability, PAVMW's ROE is +3.62%, compared to DXCM's ROE of +0.26%. Regarding short-term risk, PAVMW is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check DXCM's competition here
PAVMW vs PHG Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, PHG has a market cap of 25.8B. Regarding current trading prices, PAVMW is priced at $0.03, while PHG trades at $27.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas PHG's P/E ratio is 146.29. In terms of profitability, PAVMW's ROE is +3.62%, compared to PHG's ROE of +0.01%. Regarding short-term risk, PAVMW is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check PHG's competition here
PAVMW vs STE Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, STE has a market cap of 24.5B. Regarding current trading prices, PAVMW is priced at $0.03, while STE trades at $248.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas STE's P/E ratio is 37.95. In terms of profitability, PAVMW's ROE is +3.62%, compared to STE's ROE of +0.10%. Regarding short-term risk, PAVMW is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check STE's competition here
PAVMW vs PODD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, PODD has a market cap of 23.4B. Regarding current trading prices, PAVMW is priced at $0.03, while PODD trades at $331.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas PODD's P/E ratio is 100.86. In terms of profitability, PAVMW's ROE is +3.62%, compared to PODD's ROE of +0.18%. Regarding short-term risk, PAVMW is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check PODD's competition here
PAVMW vs ZBH Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ZBH has a market cap of 21.3B. Regarding current trading prices, PAVMW is priced at $0.03, while ZBH trades at $107.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ZBH's P/E ratio is 26.24. In terms of profitability, PAVMW's ROE is +3.62%, compared to ZBH's ROE of +0.07%. Regarding short-term risk, PAVMW is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ZBH's competition here
PAVMW vs ABMD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, PAVMW is priced at $0.03, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ABMD's P/E ratio is 65.36. In terms of profitability, PAVMW's ROE is +3.62%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, PAVMW is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ABMD's competition here
PAVMW vs SNN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SNN has a market cap of 16.3B. Regarding current trading prices, PAVMW is priced at $0.03, while SNN trades at $37.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SNN's P/E ratio is 33.31. In terms of profitability, PAVMW's ROE is +3.62%, compared to SNN's ROE of +0.09%. Regarding short-term risk, PAVMW is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SNN's competition here
PAVMW vs SWAV Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, PAVMW is priced at $0.03, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SWAV's P/E ratio is 78.76. In terms of profitability, PAVMW's ROE is +3.62%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, PAVMW is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SWAV's competition here
PAVMW vs PEN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, PEN has a market cap of 10.4B. Regarding current trading prices, PAVMW is priced at $0.03, while PEN trades at $266.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas PEN's P/E ratio is 70.43. In terms of profitability, PAVMW's ROE is +3.62%, compared to PEN's ROE of +0.12%. Regarding short-term risk, PAVMW is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check PEN's competition here
PAVMW vs ALGN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ALGN has a market cap of 10.3B. Regarding current trading prices, PAVMW is priced at $0.03, while ALGN trades at $141.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ALGN's P/E ratio is 23.95. In terms of profitability, PAVMW's ROE is +3.62%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, PAVMW is more volatile compared to ALGN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ALGN's competition here
PAVMW vs GMED Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, GMED has a market cap of 8.4B. Regarding current trading prices, PAVMW is priced at $0.03, while GMED trades at $61.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas GMED's P/E ratio is 23.98. In terms of profitability, PAVMW's ROE is +3.62%, compared to GMED's ROE of +0.09%. Regarding short-term risk, PAVMW is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check GMED's competition here
PAVMW vs BIO Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BIO has a market cap of 8B. Regarding current trading prices, PAVMW is priced at $0.03, while BIO trades at $296.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BIO's P/E ratio is 27.32. In terms of profitability, PAVMW's ROE is +3.62%, compared to BIO's ROE of +0.05%. Regarding short-term risk, PAVMW is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BIO's competition here
PAVMW vs BIO-B Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BIO-B has a market cap of 6.7B. Regarding current trading prices, PAVMW is priced at $0.03, while BIO-B trades at $247.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BIO-B's P/E ratio is -3.23. In terms of profitability, PAVMW's ROE is +3.62%, compared to BIO-B's ROE of +0.05%. Regarding short-term risk, PAVMW is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BIO-B's competition here
PAVMW vs IRTC Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, IRTC has a market cap of 5.4B. Regarding current trading prices, PAVMW is priced at $0.03, while IRTC trades at $168.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas IRTC's P/E ratio is -57.34. In terms of profitability, PAVMW's ROE is +3.62%, compared to IRTC's ROE of -1.05%. Regarding short-term risk, PAVMW is more volatile compared to IRTC. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check IRTC's competition here
PAVMW vs GKOS Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, GKOS has a market cap of 5.4B. Regarding current trading prices, PAVMW is priced at $0.03, while GKOS trades at $93.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas GKOS's P/E ratio is -58.22. In terms of profitability, PAVMW's ROE is +3.62%, compared to GKOS's ROE of -0.13%. Regarding short-term risk, PAVMW is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check GKOS's competition here
PAVMW vs BRKR Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BRKR has a market cap of 5.2B. Regarding current trading prices, PAVMW is priced at $0.03, while BRKR trades at $34.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BRKR's P/E ratio is 65.50. In terms of profitability, PAVMW's ROE is +3.62%, compared to BRKR's ROE of +0.04%. Regarding short-term risk, PAVMW is more volatile compared to BRKR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BRKR's competition here
PAVMW vs NARI Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, PAVMW is priced at $0.03, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas NARI's P/E ratio is -59.24. In terms of profitability, PAVMW's ROE is +3.62%, compared to NARI's ROE of -0.17%. Regarding short-term risk, PAVMW is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check NARI's competition here
PAVMW vs TMDX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, TMDX has a market cap of 3.9B. Regarding current trading prices, PAVMW is priced at $0.03, while TMDX trades at $115.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas TMDX's P/E ratio is 57.88. In terms of profitability, PAVMW's ROE is +3.62%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, PAVMW is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check TMDX's competition here
PAVMW vs ITGR Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ITGR has a market cap of 3.8B. Regarding current trading prices, PAVMW is priced at $0.03, while ITGR trades at $108.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ITGR's P/E ratio is 46.35. In terms of profitability, PAVMW's ROE is +3.62%, compared to ITGR's ROE of +0.05%. Regarding short-term risk, PAVMW is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ITGR's competition here
PAVMW vs AXNX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, PAVMW is priced at $0.03, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas AXNX's P/E ratio is -709.80. In terms of profitability, PAVMW's ROE is +3.62%, compared to AXNX's ROE of -0.02%. Regarding short-term risk, PAVMW is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check AXNX's competition here
PAVMW vs LIVN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, LIVN has a market cap of 3.1B. Regarding current trading prices, PAVMW is priced at $0.03, while LIVN trades at $56.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas LIVN's P/E ratio is -14.59. In terms of profitability, PAVMW's ROE is +3.62%, compared to LIVN's ROE of -0.18%. Regarding short-term risk, PAVMW is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check LIVN's competition here
PAVMW vs INSP Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, INSP has a market cap of 2.7B. Regarding current trading prices, PAVMW is priced at $0.03, while INSP trades at $91.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas INSP's P/E ratio is 54.59. In terms of profitability, PAVMW's ROE is +3.62%, compared to INSP's ROE of +0.08%. Regarding short-term risk, PAVMW is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check INSP's competition here
PAVMW vs ATEC Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ATEC has a market cap of 2.4B. Regarding current trading prices, PAVMW is priced at $0.03, while ATEC trades at $16.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ATEC's P/E ratio is -14.20. In terms of profitability, PAVMW's ROE is +3.62%, compared to ATEC's ROE of -2.52%. Regarding short-term risk, PAVMW is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ATEC's competition here
PAVMW vs PRCT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, PRCT has a market cap of 2.3B. Regarding current trading prices, PAVMW is priced at $0.03, while PRCT trades at $40.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas PRCT's P/E ratio is -26.31. In terms of profitability, PAVMW's ROE is +3.62%, compared to PRCT's ROE of -0.24%. Regarding short-term risk, PAVMW is more volatile compared to PRCT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check PRCT's competition here
PAVMW vs NUVA Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, PAVMW is priced at $0.03, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas NUVA's P/E ratio is 75.00. In terms of profitability, PAVMW's ROE is +3.62%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, PAVMW is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check NUVA's competition here
PAVMW vs AORT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, AORT has a market cap of 2.1B. Regarding current trading prices, PAVMW is priced at $0.03, while AORT trades at $44.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas AORT's P/E ratio is -102.37. In terms of profitability, PAVMW's ROE is +3.62%, compared to AORT's ROE of -0.06%. Regarding short-term risk, PAVMW is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check AORT's competition here
PAVMW vs CNMD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CNMD has a market cap of 1.7B. Regarding current trading prices, PAVMW is priced at $0.03, while CNMD trades at $54.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CNMD's P/E ratio is 15.89. In terms of profitability, PAVMW's ROE is +3.62%, compared to CNMD's ROE of +0.11%. Regarding short-term risk, PAVMW is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CNMD's competition here
PAVMW vs UFPT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, PAVMW is priced at $0.03, while UFPT trades at $218.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas UFPT's P/E ratio is 25.22. In terms of profitability, PAVMW's ROE is +3.62%, compared to UFPT's ROE of +0.19%. Regarding short-term risk, PAVMW is more volatile compared to UFPT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check UFPT's competition here
PAVMW vs SSII Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SSII has a market cap of 1.4B. Regarding current trading prices, PAVMW is priced at $0.03, while SSII trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SSII's P/E ratio is -117.83. In terms of profitability, PAVMW's ROE is +3.62%, compared to SSII's ROE of -0.71%. Regarding short-term risk, PAVMW is more volatile compared to SSII. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SSII's competition here
PAVMW vs HSKA Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, PAVMW is priced at $0.03, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas HSKA's P/E ratio is -62.49. In terms of profitability, PAVMW's ROE is +3.62%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, PAVMW is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check HSKA's competition here
PAVMW vs AHCO Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, AHCO has a market cap of 1.2B. Regarding current trading prices, PAVMW is priced at $0.03, while AHCO trades at $9.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas AHCO's P/E ratio is 17.06. In terms of profitability, PAVMW's ROE is +3.62%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, PAVMW is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check AHCO's competition here
PAVMW vs ESTA Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ESTA has a market cap of 1.2B. Regarding current trading prices, PAVMW is priced at $0.03, while ESTA trades at $41.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ESTA's P/E ratio is -13.56. In terms of profitability, PAVMW's ROE is +3.62%, compared to ESTA's ROE of -2.41%. Regarding short-term risk, PAVMW is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ESTA's competition here
PAVMW vs IART Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, PAVMW is priced at $0.03, while IART trades at $14.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas IART's P/E ratio is -2.26. In terms of profitability, PAVMW's ROE is +3.62%, compared to IART's ROE of -0.36%. Regarding short-term risk, PAVMW is more volatile compared to IART. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check IART's competition here
PAVMW vs SILK Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, PAVMW is priced at $0.03, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SILK's P/E ratio is -18.96. In terms of profitability, PAVMW's ROE is +3.62%, compared to SILK's ROE of -0.20%. Regarding short-term risk, PAVMW is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SILK's competition here
PAVMW vs FNA Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, PAVMW is priced at $0.03, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas FNA's P/E ratio is -19.83. In terms of profitability, PAVMW's ROE is +3.62%, compared to FNA's ROE of -0.36%. Regarding short-term risk, PAVMW is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check FNA's competition here
PAVMW vs INMD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, INMD has a market cap of 1B. Regarding current trading prices, PAVMW is priced at $0.03, while INMD trades at $14.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas INMD's P/E ratio is 6.25. In terms of profitability, PAVMW's ROE is +3.62%, compared to INMD's ROE of +0.27%. Regarding short-term risk, PAVMW is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check INMD's competition here
PAVMW vs IRMD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, IRMD has a market cap of 924.6M. Regarding current trading prices, PAVMW is priced at $0.03, while IRMD trades at $72.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas IRMD's P/E ratio is 45.15. In terms of profitability, PAVMW's ROE is +3.62%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, PAVMW is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check IRMD's competition here
PAVMW vs CSII Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CSII has a market cap of 844M. Regarding current trading prices, PAVMW is priced at $0.03, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CSII's P/E ratio is -20.83. In terms of profitability, PAVMW's ROE is +3.62%, compared to CSII's ROE of -0.14%. Regarding short-term risk, PAVMW is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CSII's competition here
PAVMW vs TNDM Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, TNDM has a market cap of 827.1M. Regarding current trading prices, PAVMW is priced at $0.03, while TNDM trades at $12.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas TNDM's P/E ratio is -3.97. In terms of profitability, PAVMW's ROE is +3.62%, compared to TNDM's ROE of -1.04%. Regarding short-term risk, PAVMW is more volatile compared to TNDM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check TNDM's competition here
PAVMW vs AXGN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, AXGN has a market cap of 745.9M. Regarding current trading prices, PAVMW is priced at $0.03, while AXGN trades at $16.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas AXGN's P/E ratio is -162.10. In terms of profitability, PAVMW's ROE is +3.62%, compared to AXGN's ROE of -0.04%. Regarding short-term risk, PAVMW is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check AXGN's competition here
PAVMW vs CRY Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, PAVMW is priced at $0.03, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CRY's P/E ratio is 425.71. In terms of profitability, PAVMW's ROE is +3.62%, compared to CRY's ROE of -0.05%. Regarding short-term risk, PAVMW is more volatile compared to CRY. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CRY's competition here
PAVMW vs SIBN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SIBN has a market cap of 708.4M. Regarding current trading prices, PAVMW is priced at $0.03, while SIBN trades at $16.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SIBN's P/E ratio is -28.81. In terms of profitability, PAVMW's ROE is +3.62%, compared to SIBN's ROE of -0.14%. Regarding short-term risk, PAVMW is more volatile compared to SIBN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SIBN's competition here
PAVMW vs APEN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, PAVMW is priced at $0.03, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas APEN's P/E ratio is -9.43. In terms of profitability, PAVMW's ROE is +3.62%, compared to APEN's ROE of -0.85%. Regarding short-term risk, PAVMW is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check APEN's competition here
PAVMW vs OFIX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, OFIX has a market cap of 573.1M. Regarding current trading prices, PAVMW is priced at $0.03, while OFIX trades at $14.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas OFIX's P/E ratio is -4.58. In terms of profitability, PAVMW's ROE is +3.62%, compared to OFIX's ROE of -0.25%. Regarding short-term risk, PAVMW is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check OFIX's competition here
PAVMW vs KIDS Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, KIDS has a market cap of 554.6M. Regarding current trading prices, PAVMW is priced at $0.03, while KIDS trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas KIDS's P/E ratio is -12.22. In terms of profitability, PAVMW's ROE is +3.62%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, PAVMW is more volatile compared to KIDS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check KIDS's competition here
PAVMW vs AVNS Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, AVNS has a market cap of 537.8M. Regarding current trading prices, PAVMW is priced at $0.03, while AVNS trades at $11.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas AVNS's P/E ratio is -1.16. In terms of profitability, PAVMW's ROE is +3.62%, compared to AVNS's ROE of -0.50%. Regarding short-term risk, PAVMW is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check AVNS's competition here
PAVMW vs ZIMV Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ZIMV has a market cap of 535M. Regarding current trading prices, PAVMW is priced at $0.03, while ZIMV trades at $18.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ZIMV's P/E ratio is -27.49. In terms of profitability, PAVMW's ROE is +3.62%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, PAVMW is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ZIMV's competition here
PAVMW vs CTKB Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CTKB has a market cap of 529.3M. Regarding current trading prices, PAVMW is priced at $0.03, while CTKB trades at $4.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CTKB's P/E ratio is -83.20. In terms of profitability, PAVMW's ROE is +3.62%, compared to CTKB's ROE of -0.02%. Regarding short-term risk, PAVMW is more volatile compared to CTKB. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CTKB's competition here
PAVMW vs SRDX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SRDX has a market cap of 496M. Regarding current trading prices, PAVMW is priced at $0.03, while SRDX trades at $34.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SRDX's P/E ratio is -27.98. In terms of profitability, PAVMW's ROE is +3.62%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, PAVMW is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SRDX's competition here
PAVMW vs BVS Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BVS has a market cap of 486.3M. Regarding current trading prices, PAVMW is priced at $0.03, while BVS trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BVS's P/E ratio is 242.33. In terms of profitability, PAVMW's ROE is +3.62%, compared to BVS's ROE of -0.00%. Regarding short-term risk, PAVMW is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BVS's competition here
PAVMW vs TMCI Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, TMCI has a market cap of 470M. Regarding current trading prices, PAVMW is priced at $0.03, while TMCI trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas TMCI's P/E ratio is -9.42. In terms of profitability, PAVMW's ROE is +3.62%, compared to TMCI's ROE of -0.47%. Regarding short-term risk, PAVMW is more volatile compared to TMCI. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check TMCI's competition here
PAVMW vs VREX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, VREX has a market cap of 468.1M. Regarding current trading prices, PAVMW is priced at $0.03, while VREX trades at $11.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas VREX's P/E ratio is -3.49. In terms of profitability, PAVMW's ROE is +3.62%, compared to VREX's ROE of -0.25%. Regarding short-term risk, PAVMW is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check VREX's competition here
PAVMW vs SMLR Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SMLR has a market cap of 455.8M. Regarding current trading prices, PAVMW is priced at $0.03, while SMLR trades at $30.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SMLR's P/E ratio is 6.75. In terms of profitability, PAVMW's ROE is +3.62%, compared to SMLR's ROE of +0.17%. Regarding short-term risk, PAVMW is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SMLR's competition here
PAVMW vs CBLL Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CBLL has a market cap of 420.2M. Regarding current trading prices, PAVMW is priced at $0.03, while CBLL trades at $11.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CBLL's P/E ratio is -3.35. In terms of profitability, PAVMW's ROE is +3.62%, compared to CBLL's ROE of -0.48%. Regarding short-term risk, PAVMW is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CBLL's competition here
PAVMW vs BFLY Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BFLY has a market cap of 402.8M. Regarding current trading prices, PAVMW is priced at $0.03, while BFLY trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BFLY's P/E ratio is -5.71. In terms of profitability, PAVMW's ROE is +3.62%, compared to BFLY's ROE of -0.31%. Regarding short-term risk, PAVMW is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BFLY's competition here
PAVMW vs PACB Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, PACB has a market cap of 396.5M. Regarding current trading prices, PAVMW is priced at $0.03, while PACB trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas PACB's P/E ratio is -0.59. In terms of profitability, PAVMW's ROE is +3.62%, compared to PACB's ROE of -1.89%. Regarding short-term risk, PAVMW is more volatile compared to PACB. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check PACB's competition here
PAVMW vs SENS Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SENS has a market cap of 373M. Regarding current trading prices, PAVMW is priced at $0.03, while SENS trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SENS's P/E ratio is -4.58. In terms of profitability, PAVMW's ROE is +3.62%, compared to SENS's ROE of -12.27%. Regarding short-term risk, PAVMW is more volatile compared to SENS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SENS's competition here
PAVMW vs SNWV Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SNWV has a market cap of 359.8M. Regarding current trading prices, PAVMW is priced at $0.03, while SNWV trades at $41.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SNWV's P/E ratio is -5.11. In terms of profitability, PAVMW's ROE is +3.62%, compared to SNWV's ROE of +1.45%. Regarding short-term risk, PAVMW is more volatile compared to SNWV. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SNWV's competition here
PAVMW vs BFLY-WT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BFLY-WT has a market cap of 351.7M. Regarding current trading prices, PAVMW is priced at $0.03, while BFLY-WT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BFLY-WT's P/E ratio is N/A. In terms of profitability, PAVMW's ROE is +3.62%, compared to BFLY-WT's ROE of -0.31%. Regarding short-term risk, PAVMW is more volatile compared to BFLY-WT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BFLY-WT's competition here
PAVMW vs RXST Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, RXST has a market cap of 347.8M. Regarding current trading prices, PAVMW is priced at $0.03, while RXST trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas RXST's P/E ratio is -10.62. In terms of profitability, PAVMW's ROE is +3.62%, compared to RXST's ROE of -0.12%. Regarding short-term risk, PAVMW is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check RXST's competition here
PAVMW vs CLPT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CLPT has a market cap of 302.5M. Regarding current trading prices, PAVMW is priced at $0.03, while CLPT trades at $10.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CLPT's P/E ratio is -13.30. In terms of profitability, PAVMW's ROE is +3.62%, compared to CLPT's ROE of -0.94%. Regarding short-term risk, PAVMW is more volatile compared to CLPT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CLPT's competition here
PAVMW vs BWAY Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BWAY has a market cap of 300.5M. Regarding current trading prices, PAVMW is priced at $0.03, while BWAY trades at $15.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BWAY's P/E ratio is 56.79. In terms of profitability, PAVMW's ROE is +3.62%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, PAVMW is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BWAY's competition here
PAVMW vs NPCE Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, NPCE has a market cap of 296.7M. Regarding current trading prices, PAVMW is priced at $0.03, while NPCE trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas NPCE's P/E ratio is -10.94. In terms of profitability, PAVMW's ROE is +3.62%, compared to NPCE's ROE of -1.12%. Regarding short-term risk, PAVMW is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check NPCE's competition here
PAVMW vs TCMD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, TCMD has a market cap of 289.8M. Regarding current trading prices, PAVMW is priced at $0.03, while TCMD trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas TCMD's P/E ratio is 21.31. In terms of profitability, PAVMW's ROE is +3.62%, compared to TCMD's ROE of +0.07%. Regarding short-term risk, PAVMW is more volatile compared to TCMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check TCMD's competition here
PAVMW vs VMD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, VMD has a market cap of 273.4M. Regarding current trading prices, PAVMW is priced at $0.03, while VMD trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas VMD's P/E ratio is 20.74. In terms of profitability, PAVMW's ROE is +3.62%, compared to VMD's ROE of +0.11%. Regarding short-term risk, PAVMW is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check VMD's competition here
PAVMW vs CATX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CATX has a market cap of 269.2M. Regarding current trading prices, PAVMW is priced at $0.03, while CATX trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CATX's P/E ratio is -2.65. In terms of profitability, PAVMW's ROE is +3.62%, compared to CATX's ROE of -0.32%. Regarding short-term risk, PAVMW is more volatile compared to CATX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CATX's competition here
PAVMW vs CERS Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CERS has a market cap of 255M. Regarding current trading prices, PAVMW is priced at $0.03, while CERS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CERS's P/E ratio is -13.30. In terms of profitability, PAVMW's ROE is +3.62%, compared to CERS's ROE of -0.34%. Regarding short-term risk, PAVMW is more volatile compared to CERS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CERS's competition here
PAVMW vs NNOX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, NNOX has a market cap of 253.1M. Regarding current trading prices, PAVMW is priced at $0.03, while NNOX trades at $3.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas NNOX's P/E ratio is -4.41. In terms of profitability, PAVMW's ROE is +3.62%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, PAVMW is more volatile compared to NNOX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check NNOX's competition here
PAVMW vs OM Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, OM has a market cap of 250.5M. Regarding current trading prices, PAVMW is priced at $0.03, while OM trades at $14.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas OM's P/E ratio is -0.75. In terms of profitability, PAVMW's ROE is +3.62%, compared to OM's ROE of -0.98%. Regarding short-term risk, PAVMW is more volatile compared to OM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check OM's competition here
PAVMW vs MASS Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, MASS has a market cap of 229.9M. Regarding current trading prices, PAVMW is priced at $0.03, while MASS trades at $6.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas MASS's P/E ratio is -2.70. In terms of profitability, PAVMW's ROE is +3.62%, compared to MASS's ROE of -0.13%. Regarding short-term risk, PAVMW is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check MASS's competition here
PAVMW vs NVRO Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, PAVMW is priced at $0.03, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas NVRO's P/E ratio is -1.91. In terms of profitability, PAVMW's ROE is +3.62%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, PAVMW is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check NVRO's competition here
PAVMW vs SGHT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, SGHT has a market cap of 221.5M. Regarding current trading prices, PAVMW is priced at $0.03, while SGHT trades at $4.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas SGHT's P/E ratio is -4.41. In terms of profitability, PAVMW's ROE is +3.62%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, PAVMW is more volatile compared to SGHT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check SGHT's competition here
PAVMW vs QTRX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, QTRX has a market cap of 217.9M. Regarding current trading prices, PAVMW is priced at $0.03, while QTRX trades at $4.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas QTRX's P/E ratio is -2.59. In terms of profitability, PAVMW's ROE is +3.62%, compared to QTRX's ROE of -0.22%. Regarding short-term risk, PAVMW is more volatile compared to QTRX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check QTRX's competition here
PAVMW vs INGN Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, INGN has a market cap of 216.1M. Regarding current trading prices, PAVMW is priced at $0.03, while INGN trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas INGN's P/E ratio is -7.54. In terms of profitability, PAVMW's ROE is +3.62%, compared to INGN's ROE of -0.14%. Regarding short-term risk, PAVMW is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check INGN's competition here
PAVMW vs EYES Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, EYES has a market cap of 210M. Regarding current trading prices, PAVMW is priced at $0.03, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas EYES's P/E ratio is N/A. In terms of profitability, PAVMW's ROE is +3.62%, compared to EYES's ROE of -0.26%. Regarding short-term risk, PAVMW is more volatile compared to EYES. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check EYES's competition here
PAVMW vs MGRM Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, MGRM has a market cap of 198.9M. Regarding current trading prices, PAVMW is priced at $0.03, while MGRM trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas MGRM's P/E ratio is -10.19. In terms of profitability, PAVMW's ROE is +3.62%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, PAVMW is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check MGRM's competition here
PAVMW vs CVRX Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, CVRX has a market cap of 198.2M. Regarding current trading prices, PAVMW is priced at $0.03, while CVRX trades at $7.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas CVRX's P/E ratio is -3.85. In terms of profitability, PAVMW's ROE is +3.62%, compared to CVRX's ROE of -0.79%. Regarding short-term risk, PAVMW is more volatile compared to CVRX. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check CVRX's competition here
PAVMW vs TLSI Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, TLSI has a market cap of 193.7M. Regarding current trading prices, PAVMW is priced at $0.03, while TLSI trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas TLSI's P/E ratio is -4.43. In terms of profitability, PAVMW's ROE is +3.62%, compared to TLSI's ROE of +1.27%. Regarding short-term risk, PAVMW is more volatile compared to TLSI. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check TLSI's competition here
PAVMW vs ELMD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ELMD has a market cap of 174.2M. Regarding current trading prices, PAVMW is priced at $0.03, while ELMD trades at $20.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ELMD's P/E ratio is 26.29. In terms of profitability, PAVMW's ROE is +3.62%, compared to ELMD's ROE of +0.17%. Regarding short-term risk, PAVMW is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ELMD's competition here
PAVMW vs BSGM Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, BSGM has a market cap of 165.1M. Regarding current trading prices, PAVMW is priced at $0.03, while BSGM trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas BSGM's P/E ratio is -5.02. In terms of profitability, PAVMW's ROE is +3.62%, compared to BSGM's ROE of +41.24%. Regarding short-term risk, PAVMW is more volatile compared to BSGM. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check BSGM's competition here
PAVMW vs LNSR Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, LNSR has a market cap of 150.3M. Regarding current trading prices, PAVMW is priced at $0.03, while LNSR trades at $12.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas LNSR's P/E ratio is -2.99. In terms of profitability, PAVMW's ROE is +3.62%, compared to LNSR's ROE of +51.79%. Regarding short-term risk, PAVMW is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check LNSR's competition here
PAVMW vs MXCT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, MXCT has a market cap of 148.2M. Regarding current trading prices, PAVMW is priced at $0.03, while MXCT trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas MXCT's P/E ratio is -3.31. In terms of profitability, PAVMW's ROE is +3.62%, compared to MXCT's ROE of -0.22%. Regarding short-term risk, PAVMW is more volatile compared to MXCT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check MXCT's competition here
PAVMW vs AVR Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, AVR has a market cap of 136.3M. Regarding current trading prices, PAVMW is priced at $0.03, while AVR trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas AVR's P/E ratio is -1.24. In terms of profitability, PAVMW's ROE is +3.62%, compared to AVR's ROE of -2.52%. Regarding short-term risk, PAVMW is more volatile compared to AVR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check AVR's competition here
PAVMW vs PROF Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, PROF has a market cap of 136.1M. Regarding current trading prices, PAVMW is priced at $0.03, while PROF trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas PROF's P/E ratio is -3.12. In terms of profitability, PAVMW's ROE is +3.62%, compared to PROF's ROE of -0.91%. Regarding short-term risk, PAVMW is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check PROF's competition here
PAVMW vs ANIK Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ANIK has a market cap of 134.5M. Regarding current trading prices, PAVMW is priced at $0.03, while ANIK trades at $9.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ANIK's P/E ratio is -10.98. In terms of profitability, PAVMW's ROE is +3.62%, compared to ANIK's ROE of -0.38%. Regarding short-term risk, PAVMW is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ANIK's competition here
PAVMW vs LUCD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, LUCD has a market cap of 128M. Regarding current trading prices, PAVMW is priced at $0.03, while LUCD trades at $1.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas LUCD's P/E ratio is -1.24. In terms of profitability, PAVMW's ROE is +3.62%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, PAVMW is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check LUCD's competition here
PAVMW vs OWLT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, OWLT has a market cap of 127.4M. Regarding current trading prices, PAVMW is priced at $0.03, while OWLT trades at $7.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas OWLT's P/E ratio is -1.99. In terms of profitability, PAVMW's ROE is +3.62%, compared to OWLT's ROE of +2.12%. Regarding short-term risk, PAVMW is more volatile compared to OWLT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check OWLT's competition here
PAVMW vs RCEL Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, RCEL has a market cap of 121.5M. Regarding current trading prices, PAVMW is priced at $0.03, while RCEL trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas RCEL's P/E ratio is -2.31. In terms of profitability, PAVMW's ROE is +3.62%, compared to RCEL's ROE of +279.91%. Regarding short-term risk, PAVMW is more volatile compared to RCEL. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check RCEL's competition here
PAVMW vs RPID Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, RPID has a market cap of 116.2M. Regarding current trading prices, PAVMW is priced at $0.03, while RPID trades at $2.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas RPID's P/E ratio is -2.64. In terms of profitability, PAVMW's ROE is +3.62%, compared to RPID's ROE of -0.63%. Regarding short-term risk, PAVMW is more volatile compared to RPID. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check RPID's competition here
PAVMW vs QIPT Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, QIPT has a market cap of 113.8M. Regarding current trading prices, PAVMW is priced at $0.03, while QIPT trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas QIPT's P/E ratio is -10.92. In terms of profitability, PAVMW's ROE is +3.62%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, PAVMW is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check QIPT's competition here
PAVMW vs ICAD Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, PAVMW is priced at $0.03, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas ICAD's P/E ratio is -20.37. In terms of profitability, PAVMW's ROE is +3.62%, compared to ICAD's ROE of -0.17%. Regarding short-term risk, PAVMW is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check ICAD's competition here
PAVMW vs NSPR Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, NSPR has a market cap of 103.1M. Regarding current trading prices, PAVMW is priced at $0.03, while NSPR trades at $2.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas NSPR's P/E ratio is -3.05. In terms of profitability, PAVMW's ROE is +3.62%, compared to NSPR's ROE of -1.31%. Regarding short-term risk, PAVMW is more volatile compared to NSPR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check NSPR's competition here
PAVMW vs HYPR Comparison August 2025
PAVMW plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PAVMW stands at 769.7K. In comparison, HYPR has a market cap of 99M. Regarding current trading prices, PAVMW is priced at $0.03, while HYPR trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PAVMW currently has a P/E ratio of -0.05, whereas HYPR's P/E ratio is -2.42. In terms of profitability, PAVMW's ROE is +3.62%, compared to HYPR's ROE of -0.85%. Regarding short-term risk, PAVMW is more volatile compared to HYPR. This indicates potentially higher risk in terms of short-term price fluctuations for PAVMW.Check HYPR's competition here